: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.
This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort (616 KB)
: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. : A major finding was that 41% of
Provide a breakdown of the used by the researchers in this study. Which of these would be most helpful for you? Provide a breakdown of the used by the
: For those who stopped the medication, the median time until they did so was only 7 months .
The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on: